Government must be clear on vaccine information for BAME community
The government must be clear on information about vaccine creation to help vaccine uptake in the BAME community.
Since the start of the COVID-19 pandemic...
The case for mass producing psychedelic pharmaceuticals
In this article, financial journalist Marc Davis discusses the mass production of psychedelic pharmaceuticals and the steep educational curve facing medical science.
Medical science is...
Agreement for synthesis of pharmaceutical grade psychedelic compounds
A new agreement has been struck to enable the synthesis of pharmaceutical grade psychedelic compounds in a bid to ensure there is not a...
Single-dose Janssen COVID-19 vaccine shows 66% effectiveness
New data from the Phase III studies of Janssen’s single-dose COVID-19 vaccine candidate has shown 66% effectiveness in preventing coronavirus in participants.
The UK has...
Novavax COVID-19 vaccine shows efficacy against Kent variant
Novavax has released data from its phase III COVID-19 vaccine candidate study that demonstrates it as effective against the Kent variant of the virus.
Conducted...
Malta’s ongoing commitment to the life sciences sector
Malta continues to target investment towards developing its life sciences sector and attracting international business interests
Global Ebola vaccine stockpile now established
A global stockpile of Ebola vaccines has now been established by four of the leading health and humanitarian organisations.
Led by the International Coordinating Group...
Moderna COVID-19 vaccine receives approval in UK
The British Government has now authorised the Moderna COVID-19 vaccine for use.
The Moderna COVID-19 vaccine has become the third in Britain to gain authorisation...
Lifesaving COVID-19 treatments for NHS patients
Patients in intensive care units across the UK will be receiving potentially lifesaving treatments for COVID-19.
The government-funded REMAP-CAP clinical trial has shown that the...
Second COVID-19 vaccine authorised by the European Commission
The European Commission has granted conditional marketing authorisation (CMA) for the Moderna COVID-19 vaccine – the second one to be authorised in the EU.
The...
Natural compounds could disrupt future virus pandemics
A team of researchers have explored the genomic and life history traits of three classes of viruses that have contributed to historical global pandemics...
WHO lists Pfizer/BioNTech COVID-19 vaccine for emergency use
As more countries across the globe begin rolling out their mass COVID-19 vaccination programmes, the World Health Organization (WHO) has now listed the Pfizer/BioNTech...
New pathway for approval of medicines in the UK
A new pathway for the approval of medicines in the UK has opened, aiming to bring closer collaboration between authorities and bodies and helping...
Treating brain disorders with new nanoparticle drug delivery system
A new nanoparticle drug-delivery system could help scientists overcome the long-standing problem of delivering therapeutics across the blood-brain barrier and into the brain.
Progress has...
Oxford University COVID-19 vaccine roll out begins
The first person in the UK has now received the Oxford University and AstraZeneca COVID-19 vaccine, which has begun its NHS roll out today.
The...
UK’s first investment fund dedicated to psychedelic healthcare
In a first for the UK, an investment fund dedicated to psychedelic healthcare has been launched.
The new fund comes as recent rigorous clinical trials...
European Commission concludes Novavax talks for COVID-19 vaccine
The European Commission has concluded its talks with pharmaceutical company Novavax regarding the purchase of its potential COVID-19 vaccine.
The European Commission and Novavax envisaged...
Renewed collaboration to eliminate tropical diseases
A decades-long collaboration between the World Health Organization (WHO) and Sanofi has been renewed in order to sustain efforts to eliminate neglected tropical diseases.
The...
Clinical trials for another COVID-19 vaccine begin in UK
Early Phase I and Phase II clinical trials have started in the UK for the Valneva COVID-19 vaccine, which is to be tested on...
Pritelivir Phase III clinical trials for HSV immunocompromised patients
The medicine Pritelivir is to enter Phase III clinical trials for the treatment of immunocompromised patients who have acyclovir-resistant mucocutaneous herpes simplex virus (HSV)...
